VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

PROSCA/BLADDR 2020 | Genomic testing in prostate cancer

Emmanuel Seront • 7 Oct 2020
PROSCA/BLADDR 2020
Genitourinary Cancer Prostate Cancer Olaparib

Emmanuel Seront, MD, PhD, Jolimont Hospital, La Louvière, Belgium, outlines the use of genomic testing in prostate cancer as well as abnormalities seen in these patients that influence prognosis including BRCA mutated patients that can be targeted using olaparib. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Emmanuel Seront

0:53
Immunotherapy in prostate cancer
Emmanuel Seront • 7 Oct 2020
1:22
Advances in non-metastatic castration-resistant prostate cancer
Emmanuel Seront • 14 Oct 2020

Related Videos

3:37
Challenges of MRI in prostate cancer
Anwar Padhani • 14 Oct 2020
4:34
Optimising treatment for advanced urothelial cancer: combination, maintenance or sequencing?
Arlene Siefker-Radtke • 14 Oct 2020
1:41
Challenges and treatment advances in mHSPC
Ursula Vogl • 14 Oct 2020
1:25
Improving precision of high-quality prostate cancer MRI
Anwar Padhani • 14 Oct 2020
VJOncology VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJOncology is intended for healthcare professionals